What Диспорт treats: Main Uses and Benefits

The primary role of this medication is to provide supportive symptomatic relief in clinical settings marked by increased neurological or muscular activity that can create noticeable physiological strain. Therapeutic application is commonly utilized in addressing conditions where localized, excessive muscle or gland function creates a significant symptomatic burden.

---

Treatment of Persistent Spasticity and Focal Dystonia

This medicine is commonly used for managing symptom clusters that create noticeable functional strain, such as muscle stiffness (spasticity) and involuntary contractions (dystonia) in specific body areas. This is applied across chronic neurological conditions to ease the overall symptom burden. Key indications include managing the symptomatic burden of spasticity in the upper and lower limbs, addressing cervical dystonia, and easing the manifestations of blepharospasm. The supportive relief may assist with the functional strain on mobility and contributes to rehabilitation efforts.

---

Relief from Localized Functional Hyperactivity

Диспорт is relevant for easing symptoms linked to organ-specific functional stress or heightened physiological activity in highly localized areas. This includes managing symptoms related to conditions such as primary axillary hyperhidrosis (excessive sweating) and hemifacial spasm. The treatment may assist with the appearance of moderate to severe glabellar lines (frown lines) in adults, offering symptomatic relief for dynamic lines.

---

Quick Fact: Relief for Symptoms of Increased Neurological or Muscular Activity

This medication is commonly used to help with symptoms related to sustained muscle spasm or hyper-function, thereby assisting with maintaining functional stability during symptomatic periods.

Диспорт (AbobotulinumtoxinA) eligibility is determined by official governmental regulatory bodies based on absolute contraindications, age, and specific pre-existing health conditions.

Contraindications

Use of Диспорт is absolutely prohibited (contraindicated) in patients with a known hypersensitivity or allergy to abobotulinumtoxinA, any component in the formulation, or cow's milk protein. It is also prohibited if there is an active infection at the planned injection site.

Age and Use Limitations

Eligibility is indication-specific and subject to age thresholds:

• Adults are indicated for therapeutic conditions such as cervical dystonia.
• Adults under 65 years of age are eligible for the cosmetic indication (glabellar lines).
• Children 2 years of age and older are eligible for spasticity treatment; safety and effectiveness are not established for children under two years.

Restricted Populations

The medicine must be administered with caution to individuals with pre-existing neuromuscular junction disorders (like ALS or Myasthenia Gravis) or those with swallowing or breathing difficulties, due to increased susceptibility to the spread of the toxin's effect. Use during pregnancy or lactation is conditional and only advised if the potential benefit outweighs the potential risk.

Interactions with other medicines and products

Official regulatory documentation structures the interaction profile of Диспорт ( AbobotulinumtoxinA) based primarily on pharmacodynamic potentiation and specific co-administration restrictions.

---

Interaction Classifications and Restrictions

Interactions resulting in Potentiation (Use with Caution): The effect of AbobotulinumtoxinA may be potentiated when co-administered with certain medicines that also affect neuromuscular function. These include aminoglycoside antibiotics, neuromuscular blocking agents (such as curare-like agents), and other muscle relaxants. The outcome of this interaction is described as an additive functional effect, increasing the risk of excessive muscle weakness. Similarly, anticholinergic drugs may potentiate systemic anticholinergic effects.

Contraindications and Administration Constraints: Co-administration is contraindicated in patients with known hypersensitivity to cow's milk protein, an excipient in the formulation. The effects of administering AbobotulinumtoxinA within several months of other botulinum toxin products are officially unknown, and such practice is not advised. The regulatory labels do not document mandatory timing separation requirements for co-administered medicines, nor do they list known interactions with foods or drinks.

Population-Specific Caution: The risk of clinically significant effects from these interactions is officially noted as increased for individuals with pre-existing neuromuscular disorders.

How Диспорт Works: Mechanism of Action

The mechanism of Диспорт (AbobotulinumtoxinA) is defined by its specific, localized action that interrupts the communication between nerve and muscle.

Targeted Inhibition of Acetylcholine Release

Диспорт functions as a selective enzyme that specifically targets the presynaptic motor nerve terminal . After binding and internalization, the active part of the toxin cleaves the essential protein SNAP-25. This cleavage prevents the molecular machinery (SNARE complex) from completing the vesicle fusion required for releasing the neurotransmitter acetylcholine (ACh). This action abolishes the chemical signal required for muscle contraction.

Causal Cascade and Localized Functional Blockade

The resulting failure of acetylcholine release leads to a functional blockade of neuromuscular transmission. This interruption creates a state of temporary chemical denervation, which directly results in the physiological consequence: a reduction in muscle fiber excitability due to the absence of efferent nerve signaling. The effect is delayed, as it depends on the kinetics of cellular uptake and enzymatic cleavage, and is temporary, as the body's natural nerve regeneration processes eventually restore signal transmission.

The use of Диспорт is a specialized procedure defined by established clinical protocols. The medicine is supplied as a sterile powder for solution for injection that must be prepared by a healthcare professional immediately prior to use. Administration is restricted to intramuscular (IM) injection directly into the specific muscles requiring treatment.

Administration and Dosing

Before injection, the lyophilized powder must be reconstituted using a specific volume of preservative-free 0.9% Sodium Chloride Injection and aseptic technique. The appropriate Unit dose is highly specific to the indication, such as cervical dystonia or limb spasticity. For adult spasticity, a maximum total dose of 1500 Units is established for administration in a single treatment session. The Unit dose calculation is unique to this product, and its potency is not interchangeable with the Units of any other botulinum toxin product.

Frequency and Scheduling

The treatment is administered intermittently, and subsequent injections are scheduled based on the return of clinical symptoms. For therapeutic uses, standard protocols involve a minimum interval of 12 weeks between treatments to allow for the full duration of effect to diminish before re-injection occurs. For pediatric patients (ages 2 years and older), dosing is calculated on a Units/kg basis, with distinct maximum limits for upper and lower limb spasticity.

Research Evidence / Overview of Studies for Диспорт (AbobotulinumtoxinA)

The clinical evaluation of Диспорт is based on formal controlled studies, primarily Randomized Controlled Trials (RCTs), followed by multi-year open-label studies and observational research. This evidence is used in research exploring how symptoms change over time and is applied in research contexts involving conditions characterized by functional limitations due to excessive muscle activity.

---

Evidence for Managing Muscle Spasticity

This section summarizes the formal clinical evaluations that contributed to the research base for the clinical evaluation of Диспорт in conditions involving muscle stiffness (spasticity) in both the upper and lower limbs of adults.

For upper limb spasticity in adults, research examined short-term RCTs, primarily tracking changes in muscle tone using scales like the Modified Ashworth Scale (MAS). Findings describe patterns observed in the measured outcomes related to muscle tone during the study period. However, research notes that functional measures, such as those related to daily activity level, were less consistently observed in single-cycle trials than the changes in muscle tone.

Evidence for Lower Limb Spasticity in Children

The research examined changes in muscle tone and studies monitored outcomes related to individualized, patient-specific goals defined before treatment. It is important to note that formal clinical research has not established the effectiveness or safety in pediatric patients below the age of two years. Data for certain groups remain insufficient, specifically concerning injections into the more proximal muscles in the lower limbs.

---

Evidence for Addressing Focal Involuntary Contractions (Dystonia)

Studies exploring cervical dystonia monitored outcomes capturing phases of heightened symptom activity, such as changes in the Toronto Western Spasmodic Torticollis Rating Scale (TWSTRS) score. Findings describe patterns observed in these measured components when compared to control groups over defined time intervals. Limited information is available regarding whether using different guidance techniques during the injection process impacts long-term results.

---

Research Gaps and Areas of Uncertainty

Long-term effects are not fully established for all functional markers. Data related to functional outcomes appear to require extended follow-up and repeated dosing, and certainty remains low regarding these specific long-term outcomes. Subgroup findings are uncertain for specific patient groups, such as very young children, and evidence quality varies across studies when assessing patients with complex conditions and varying symptom burdens.

Common questions about Диспорт (FAQ)

Q: What is the primary action or function of Диспорт?

According to the official product information, Диспорт (Dysport) is classified as a peripheral muscle relaxant. Regulatory documents describe its mechanism as blocking nerve impulses, which may cause temporary muscle relaxation. It is indicated for treating specific conditions involving excessive muscle activity or spasms.

---

Q: What types of ingredients are found in Диспорт?

The main active substance in Диспорт is botulinum toxin type A, derived from Clostridium botulinum bacteria. The official product information states that it also contains inactive ingredients, known as excipients, such as human albumin and lactose. Official product information lists all components, and patients should be aware of these ingredients.

---

Q: What are the approved medical conditions for treating with Диспорт?

Regulatory documents state that Диспорт is approved for conditions like focal spasticity of the upper or lower limbs in adults and certain forms of cervical dystonia (spasmodic torticollis). It is also indicated for cosmetic treatment, specifically for the temporary reduction of the appearance of glabellar frown lines.

---

Q: How long does it typically take for the effects of Диспорт to become noticeable after injection?

Studies and official information indicate that the time until the onset of effect for Диспорт varies depending on the specific condition being treated. For the treatment of glabellar lines, the onset of effect has been observed to begin within 2 to 3 days after the injection. For other conditions like cervical dystonia, the effect is generally noticeable within a week.

---

Q: How long do the therapeutic effects of Диспорт generally last?

According to the official product information, the therapeutic effect of Диспорт is temporary. For muscle spasticity in adults and children, the effect may last approximately 12 to 16 weeks (3 to 4 months). For cosmetic treatments, effects have been reported to last up to 4 months.

---

Q: Can Диспорт be used in pediatric patients, and if so, for what conditions?

Yes, regulatory documents state that Диспорт is approved for use in pediatric patients for specific indications. It is indicated for the treatment of dynamic equinus foot deformity, which is caused by spasticity in children with cerebral palsy who are two years of age or older. Its use is restricted to specific approved conditions and defined age groups, as detailed in the official label.

The official storage and disposal requirements for Диспорт (AbobotulinumtoxinA) are strictly defined by regulatory documents. The product, a powder for solution for injection, must be stored under refrigeration at 2 C to 8 C (36 F to 46 F) and must be protected from light.

---

Storage Classification	Requirement
Temperature	mathbf2^circC to 8^circC (refrigerated)
Protection	Protect from light; Do not freeze reconstituted solution
Stability	Use within 24 hours after reconstitution

---

Диспорт is supplied in single-use vials. The reconstituted solution must be stored in the original container and must be discarded if not used within the 24-hour stability period. Disposal of any unused product, the vial, and the needle must be conducted in accordance with local regulations governing controlled waste. Additionally, the medicine must be stored out of the sight and reach of children.